Syncom Formulations (India) Ltd. (SYNCOMF): Syncom Formulations 52 Week High Streak: Second Straight Session
- September 29, 2026
- Posted by: Chaitanya Auti
- Category: News
Syncom Formulations 52 Week High Streak has now extended to its second straight session, with the stock trading within 2% of its 52-week high across the streak. The latest reading shows a cumulative move of 16.1% across that run, while the current level of Rs 23.29 sits close to the latest peak of Rs 23.49. The latest Univest figures confirm the price pattern, but they do not establish a company-specific catalyst for the continued move.
In today’s market action, Syncom Formulations last traded at Rs 23.29 against the previous close of Rs 22.2, after opening at Rs 22.36 and moving between Rs 22.06 and Rs 23.49. With a market capitalisation of Rs 1,885.64 crore, the stock is being watched for what a repeated near-high pattern says about price behaviour versus a one-day move.
Syncom Formulations 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 23.29 |
| Previous Close | Rs 22.2 |
| Today's Move | +Rs 1.09 (+4.91%) |
| Open | Rs 22.36 |
| High | Rs 23.49 |
| Low | Rs 22.06 |
| Market Capitalisation | Rs 1,885.64 crore |
Syncom Formulations (India) Ltd. (SYNCOMF) traded at Rs 23.29 versus the previous close of Rs 22.2, a rise of 4.91%. The stock opened at Rs 22.36, reached a high of Rs 23.49 and touched a low of Rs 22.06.
Syncom Formulations Share Price Today shows a clear gap between the latest trade and the prior close, with the stock up Rs 1.09 or 4.91% from Rs 22.2. The day began at Rs 22.36, dipped to Rs 22.06 and touched Rs 23.49, leaving the latest price near the top of the day’s range. For readers tracking the Syncom Formulations Share Price, this is more than a routine move because it comes while the stock remains in a 52 Week High Streak context.
The important distinction is that this is not being read as a fresh record claim. The stock is trading close to its yearly peak, and the repeated placement near that level keeps Syncom Formulations stock news in focus. As a Stocks In News Today name, it is being followed less for a single intraday print and more for the fact that the latest price has stayed near the high across multiple sessions. That is the core of the Syncom Formulations Consecutive 52 Week High setup.
For market participants using Syncom Formulations Share Price Update style searches, the session shows that the stock has held well above the opening level and stayed within striking distance of the upper end of the day’s band. The same move also places it among 52 Week High Stocks that continue to stay on watch lists when a stock price remains near a yearly peak.
What the Repeated 52-Week Highs Show
Syncom Formulations 52 Week High Streak matters because the current pattern spans two consecutive sessions, not one isolated print. The stock has traded within 2% of its 52-week high for its second straight session, and the cumulative gain across that streak is 16.1%. That tells readers where the move sits in time, even if it does not explain why the price has held near the high.
The current streak also shows how close the market is trading to the latest annual peak of Rs 23.49. The gap between the current price and that peak is narrow, which is why searches such as Syncom Formulations New One Year High, Syncom Formulations Back To Back 52 Week Highs and Stocks At One Year High Today are relevant to this name. The latest Univest figures confirm a repeated near-high pattern, but they do not identify a new trigger on their own.
Syncom Formulations (India) Ltd. (SYNCOMF) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,885.64 crore |
| P/E Ratio | 24.4x |
| P/B Ratio | 4.74x |
| ROE | 20.19% |
| ROCE | 26.8% |
| EPS | Rs 0.91 |
| Book Value Per Share | Rs 4.68 |
| Dividend Yield | 0.45% |
Syncom Formulations (India) Ltd. (SYNCOMF) fundamental metrics show P/E 24.4x, P/B 4.74x, ROE 20.19%, ROCE 26.8%. These figures provide context only and are not a buy or sell signal.
Syncom Formulations (India) Ltd. has a market capitalisation of Rs 1885.64 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 24.4x, P/B at 4.74x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 20.19% and ROCE of 26.8%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 0.91, book value per share of Rs 4.68, dividend yield of 0.45%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 28.3x, median ROE of 11.7%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 24.4x |
| Benchmark Median P/E | 28.3x |
| Benchmark Average P/E | 41.7x |
| Benchmark P/E Range | 0x to 707.31x |
| Company P/B Ratio | 4.74x |
| Benchmark Median P/B | 2.83x |
| Company ROE | 20.19% |
| Benchmark Median ROE | 11.7% |
| Company ROCE | 26.8% |
| Benchmark Median ROCE | 13.46% |
| Company Market Capitalisation | Rs 1,885.64 crore |
| Benchmark Median Market Cap | Rs 782.41 crore |
Syncom Formulations (India) Ltd. (SYNCOMF) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Syncom Formulations (India) Ltd. (SYNCOMF) has a P/E ratio of 24.4x, which is below the benchmark median of 28.3x, a difference of -13.78%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Syncom Formulations (India) Ltd. (SYNCOMF) has a ROE of 20.19%, which is above the benchmark median of 11.7%, a difference of +72.56%. Syncom Formulations (India) Ltd. (SYNCOMF) has a ROCE of 26.8%, which is above the benchmark median of 13.46%, a difference of +99.11%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Hester Biosciences Ltd. | HESTERBIO | 1,857.9 | 13.37 | 4 | 17.05 | 16.21 |
| NGL Fine-Chem Ltd. | NGLFINE | 1,800.49 | 29.49 | 4.85 | 15.74 | 16.88 |
| ANLON HEALTHCARE LIMITED | AHCL | 1,680.12 | 64.81 | 6.34 | 18.73 | 21.98 |
| Accent Microcell Ltd. | ACCENTMIC | 1,623.7 | 37.02 | 5.89 | 18.65 | 24.88 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,226.41 | 136.4 | 2.89 | 4.88 | 6.1 |
Syncom Formulations (India) Ltd. (SYNCOMF) has a P/E ratio of 24.4x compared with the displayed peer median of 37.02x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 20.19% compares with a peer median of 17.05% across the companies shown in the table. ROCE stood at 26.8% versus the displayed peer median of 16.88%, providing a capital-efficiency comparison. Syncom Formulations (India) Ltd. (SYNCOMF) has a market capitalisation of Rs 1,885.64 crore. Among the 5 peers shown, 1 has a larger market capitalisation.
Why Investors Are Watching Syncom Formulations
- The stock has traded within 2% of its 52-week high for its second straight session.
- The cumulative move across the streak is 16.1%, which keeps Syncom Formulations 52 Week High Streak in focus.
- The latest price of Rs 23.29 remains close to the recent peak of Rs 23.49.
- The company’s P/E of 24.4 is below the industry median in Pharmaceuticals & Drugs.
- The company’s ROE and ROCE are above the industry medians, which adds to Syncom Formulations Stock Performance interest.
About Syncom Formulations (India) Ltd.
Syncom Formulations (India) Ltd. operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. The company’s market capitalisation stands at Rs 1,885.64 crore, placing it among closely watched mid-sized names in the space. The stock is listed on NSE and BSE, and the latest read places it near its one-year peak again.
For readers searching Syncom Formulations Company News or Syncom Formulations Stock News, the important point is that the current article focuses on the repeated near-high pattern, valuation context and sector comparison rather than on a one-off move. That makes it useful for tracking how the Syncom Formulations Share Price is behaving over multiple sessions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
What does the Syncom Formulations 52 Week High Streak mean?
Ans. It means Syncom Formulations has traded within 2% of its 52-week high for two straight sessions. The streak highlights repeated proximity to the yearly peak and helps explain why the stock remains on market watch lists.
How many sessions has Syncom Formulations stayed near its high?
Ans. According to the latest Univest figures, Syncom Formulations has stayed near its 52-week high for two consecutive sessions. That is the core of the current Syncom Formulations 52 Week High Streak story.
What is the cumulative move across the streak?
Ans. The cumulative move across the streak is 16.1%. This is the most important differentiator versus a single-day breakout story because it shows the full movement across both sessions.
Did Syncom Formulations make a new 52-week high today?
Ans. The price moved close to the latest peak of Rs 23.49, but this article does not claim a fresh record unless the data explicitly shows it. The focus here is the repeated near-high pattern, not a new high claim.
Is a company-specific catalyst confirmed for the move?
Ans. No company-specific catalyst is confirmed by the latest figures. The pattern confirms repeated trading near the 52-week high, but it does not establish a reason for the move.
How does the valuation look in the industry context?
Ans. Syncom Formulations trades at a P/E of 24.4, below the industry median of 28.3, while its P/B of 4.74 is above the median of 2.83. The mix points to a valuation that is neither stretched nor cheap in absolute terms.
How do the return ratios compare with peers?
Ans. The company’s ROE of 20.19% and ROCE of 26.8% compare well with many peers in Pharmaceuticals & Drugs. Those ratios are stronger than several names in the peer set and above the industry median levels.
What should investors track next in Syncom Formulations Stock News?
Ans. Investors can track whether the stock keeps trading near its 52-week high, whether the current level holds above the prior day’s close, and whether company updates or sector moves change the current Syncom Formulations Share Price pattern.
Track Syncom Formulations (India) Ltd. (SYNCOMF) Share Price on Univest
Use Syncom Formulations (India) Ltd. (SYNCOMF) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.